Patents Assigned to Campina Nederland Holding B.V.
-
Patent number: 8999923Abstract: The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin.Type: GrantFiled: June 15, 2009Date of Patent: April 7, 2015Assignee: Campina Nederland Holding B.V.Inventors: Linqiu Cao, Hans Maas
-
Patent number: 8865778Abstract: A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or sodium starch glycolate (SSG), and a hydrophilic, non-ionic cellulose ether, preferably hydroxypropylmethylcellulose. Whether or not a SSG in the mixture is sufficiently uncross-linked in the context of the invention can be determined by sedimentation: 0.25 g of the formulation in 100 ml deionized water after 24 hours at 25° C., if subjected to centrifugation at 6080 G at 25° C. for 15 minutes, should exhibit a sedimentation volume of more than 60 ml.Type: GrantFiled: December 4, 2007Date of Patent: October 21, 2014Assignee: Campina Nederland Holding B.V.Inventors: Linqiu Cao, John Richard Langridge, Alexander Wilhelmus Van Gessel
-
Patent number: 8431531Abstract: A protein hydrolysate having a degree of hydrolysis between 1 and 40% and containing between 1 and 70 wt. % of peptides having a molecular weight of less than 500 Da and less than 55 wt. % of peptides or proteins having a molecular weight of more than 5000 Da, on the basis of the total proteinaceous material of the composition, is effective in stimulating secretion of glucagon-like peptide-1 (GLP-1). In addition, the hydrolysate may have DPP-IV inhibiting activity. The hydrolysate is suitable for the manufacture of a medicament, or food product for prophylaxis and/or treatment of a GLP-1 mediated condition, in particular obesity, type 2 diabetes mellitus and an immunological disorder.Type: GrantFiled: November 30, 2006Date of Patent: April 30, 2013Assignee: Campina Nederland Holding B.V.Inventor: Jan-Willem Pieter Boots
-
Patent number: 8273710Abstract: Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.Type: GrantFiled: November 30, 2005Date of Patent: September 25, 2012Assignee: Campina Nederland Holding B.V.Inventor: Jan-Willem Pieter Boots
-
Patent number: 8263164Abstract: A heat stable nutritional beverage having a pH of 6.6-8.2 comprising 5-12% w/w whey protein is obtained by incorporating 4-16% w/w of at least one sugar selected from di-oligo- and polysaccharides, wherein at least one monosaccharide is other than glucose.Type: GrantFiled: July 9, 2008Date of Patent: September 11, 2012Assignee: Campina Nederland Holding B.V.Inventors: Pauline Elisabeth Antoinette Smulders, Marco Albertus Franciscus Johannes Somers
-
Patent number: 8173173Abstract: The invention relates to a process for the preparation of anhydrous lactose agglomerates, said process comprising (i) subjecting essentially anhydrous lactose primary particles comprising at least 60 wt % crystalline-lactose in a granulator to a wet granulation step at a temperature in the range of 30-100° C. using a binder solution, wherein the granulation mass is subjected to drying for at least part of the granulation step, and (ii) after-drying the granulation mass. The anhydrous lactose agglomerates thus produced comprise at least 50 wt %-lactose crystallites and have a total water content in the range of 0-1.0 wt %, which is required according to the standards laid down by the Pharmacopoeia for anhydrous lactose excipients. These agglomerates combine have excellent compactibility and flowability properties and are particularly useful as excipient in moisture-sensitive applications.Type: GrantFiled: December 21, 2005Date of Patent: May 8, 2012Assignee: Campina Nederland Holding B.V.Inventors: Klaas Daniël Kussendrager, Bouwe Walsma
-
Patent number: 8147875Abstract: The invention provides a method for the treatment of acne comprising orally administering to a person suffering from acne an effective amount of a whey protein fraction containing lactoferrin, and preferably containing further specific whey proteins. The lactoferrin is preferably native bovine lactoferrin and the whey protein fraction is administered at a level of between 10 mg and 2 g lactoferrin per patient per day.Type: GrantFiled: March 14, 2006Date of Patent: April 3, 2012Assignee: Campina Nederland Holding B.V.Inventors: Rick De Waard, Angela Loriann Walter
-
Publication number: 20100203026Abstract: The invention relates to the field of nutrition and medicine. Provided are compositions, bacterial strains and methods for inducing or enhancing satiety and satiation and for treating or preventing obesity, overweight and overweight related diseases.Type: ApplicationFiled: July 25, 2007Publication date: August 12, 2010Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventors: Marta Zdzislawa Korczynska, Wouter Noordman, Arthur Constantijn Ouwehand
-
Publication number: 20100087549Abstract: A controlled release excipient composition suitable in formulation of a slow or extended release tablet, contains a synergistic mixture of substantially uncross-linked carboxymethyl starch, or sodium starch glycolate (SSG), and a hydrophilic, non-ionic cellulose ether, preferably hydroxypropylmethylcellulose. Whether or not a SSG in the mixture is sufficiently uncross-linked in the context of the invention can be determined by sedimentation: 0.25 g of the formulation in 100 ml deionized water after 24 hours at 25° C., if subjected to centrifugation at 6080 G at 25° C. for 15 minutes, should exhibit a sedimentation volume of more than 60 ml.Type: ApplicationFiled: December 4, 2007Publication date: April 8, 2010Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventors: Linqiu Cao, John Richard Langridge, Alexander Wilhelmus Van Gessel
-
Publication number: 20100056458Abstract: The invention provides novel peptides having ACE-inhibiting properties derived from milk proteins, as well as their mixtures and their use as hypotensive aids. The peptides have from 2 up to 14 amino acid residues, at least one of which is a branched-chain amino acid. Examples include IV, LV, VLGPV, VPYPQ, VPYPQR, AVP, KIHP, KYKVPQL, FFVAPFPEVFG, VAPFPEVF, MKGLDI, KGLDI, LR, MHIRLS, MHI, IIA, IAEKT, LKALP, ALP and KK. The invention also provides a process of producing the peptide by enzymatic hydrolysis of milk proteins or other proteins.Type: ApplicationFiled: June 29, 2006Publication date: March 4, 2010Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventors: Jenneke Adriana Cadee, Leon Franciscus Mallee
-
Publication number: 20090081308Abstract: The invention relates to a process for the preparation of anhydrous lactose agglomerates, said process comprising (i) subjecting essentially anhydrous lactose primary particles comprising at least 60 wt % crystalline-lactose in a granulator to a wet granulation step at a temperature in the range of 30-100° C. using a binder solution, wherein the granulation mass is subjected to drying for at least part of the granulation step, and (ii) after-drying the granulation mass. The anhydrous lactose agglomerates thus produced comprise at least 50 wt %-lactose crystallites and have a total water content in the range of 0-1.0 wt %, which is required according to the standards laid down by the Pharmacopoeia for anhydrous lactose excipients. These agglomerates combine have excellent compactibility and flowability properties and are particularly useful as excipient in moisture-sensitive applications.Type: ApplicationFiled: December 21, 2005Publication date: March 26, 2009Applicant: Campina Nederland Holding B.V.Inventors: Klaas Daniel Kussendrager, Bouwe Walsma
-
Publication number: 20090074893Abstract: The invention provides a method for the prevention or treatment of virus infections comprising administering, to a human or animal individual susceptible to or suffering from a virus infection, an effective amount of one or more casein phosphopeptides (CPP). Also provided is a composition containing such casein peptides and further agents such as vitamin C and/or nutritional components for use in treating or preventing virus infections.Type: ApplicationFiled: April 28, 2006Publication date: March 19, 2009Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventors: Rick de Waard, Yves Pouliot, Christina Juneau, Leon Franciscus Mallee
-
Publication number: 20090075904Abstract: Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.Type: ApplicationFiled: November 30, 2005Publication date: March 19, 2009Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventor: Jan-Willem Pieter Boots
-
Publication number: 20080032915Abstract: Described is the use of a mixture of peptides, the peptides comprising at least 6.5% wt cysteine, for the manufacture of a medicament, supplement, beverage or food product for restoring thiol homeostasis. Furthermore, a method is described for restoring thiol homeostasis in a subject in need thereof, said method comprising administering to said subject an effective amount of a mixture of peptides, the peptides comprising at least 6.5% wt cysteine.Type: ApplicationFiled: February 12, 2004Publication date: February 7, 2008Applicant: CAMPINA NEDERLAND HOLDING B.V.Inventors: Rijkje Cornelia Sprong, Steffi Dudek, Fiona Marie Taylor